Introduction
Proteases regulate autocrine and paracrine signaling of growth factors and chemokines, thereby promoting or inhibiting tumor growth and metastasis (Kenny et al., 1989; Ghersi et al., 2002; Nanus, 2003; Bauvois, 2004; Carl-McGrath et al., 2006; Bonfil et al., 2007; Golubkov and Strongin, 2007) . However, the contribution of proteases and chemokines to neuroblastoma (NB) is not well understood. NB, the most common solid tumor of childhood, originates from the sympatho-adrenal lineage and remains the second major cause of deaths among children (Matthay, 2008) . NB consists of neural crest-derived, undifferentiated cells and is notable for its spontaneous regression to aggressive metastatic growth (Brodeur, 2003; Nakagawara, 2004; Tucker, 2004; Castel et al., 2007; Maris et al., 2007; Matthay, 2008) . Therapy-resistant aggressive NBs frequently overexpress and secrete high levels of growth factors and chemokines (Nakagawara et al., 1994; Eggert et al., 2000; Geminder et al., 2001; Vasudevan et al., 2005; Ren et al., 2006; Li and Thiele, 2007) .
Chemokines and their receptors activate growth signaling pathways and matrix metalloproteinases, thereby providing a microenvironment suitable for tumor growth, migration, invasion and angiogenesis (Gerard and Rollins, 2001; Barbero et al., 2003; Tanaka et al., 2005; Burger and Kipps, 2006; Chinni et al., 2006; Singh et al., 2007) . Growing evidence implicates the chemokine stromal-derived factor 1 (SDF1/CXCL12) and its receptor CXCR4, which normally controls neural crest development, as having important roles in tumor growth, angiogenesis and metastasis of various cancers including NB (Geminder et al., 2001; Payne and Cornelius, 2002; Tran et al., 2004; Belmadani et al., 2005; Airoldi et al., 2006; Guyon and Nahon, 2007) . Elevated expression of SDF1 and CXCR4 in NB tumors is significantly correlated with tumor grade, poor clinical outcome and metastasis to the bone marrow that expresses high levels of SDF1 (Russell et al., 2004) .
Dipeptidyl peptidase IV (DPPIV), a serine protease, is mainly expressed on the cell surface in neurons, epithelial cells, thymus and melanocytes (Schrader et al., 1987; Dinjens et al., 1990; Abbott et al., 1997; Wesley et al., 1999 Wesley et al., , 2004 Wesley et al., , 2005 Gabrilovac et al., 2003) . It is also present as a soluble form, circulating in the serum (Durinx et al., 2000; Christopherson et al., 2002; Havre et al., 2008) . DPPIV cleaves N-terminal dipeptides from selected bioactive peptides, including some chemokines and neuropeptides, leading to their inactivation and/or degradation (Proost et al., 1998; Shioda et al., 1998; Mentlein, 1999; Durinx et al., 2000; Lambeir et al., 2001; Scharpe and De Meester, 2001) . Indeed, loss or alteration of DPPIV expression is linked to the development of several tumors, including prostate, lung, breast, hepatocellular carcinomas, ovarian cancer and melanomas (Morrison et al., 1993; Sakamoto et al., 1993; Bogenrieder et al., 1997; Tsuji et al., 2004; Wesley et al., 2005) . Independent of its enzymatic activity, DPPIV interacts with extracellular matrix (ECM) components, including collagen and fibronectin, thus regulating cell-cell and cell-ECM interactions (Piazza et al., 1989; Sedo and Kraml, 1994; Dobers et al., 2000; Havre et al., 2008) . Through these functions, DPPIV regulates diverse biological processes, including cell differentiation, adhesion, immune modulation and apoptosis, functions that control neoplastic transformation. Earlier, we and others have shown that DPPIV indeed suppresses the malignant phenotype of melanomas, prostate, ovarian and lung cancers (Wesley et al., 1999 (Wesley et al., , 2004 (Wesley et al., , 2005 Pethiyagoda et al., 2000; Kajiyama et al., 2006) . These studies support a role for DPPIV as a tumor suppressor gene.
In this study, we report that DPPIV is expressed in normal sympathetic nervous system-derived structures, but its expression and enzymatic activities are greatly decreased in cell lines derived from NB. We further demonstrate that DPPIV re-expression suppresses the malignant phenotype of NB cells, as indicated by inhibition of tumor growth, cell migration and angiogenesis, in association with induction of apoptosis mediated by caspase activation. DPPIV restoration downregulated several chemokines, including SDF1 and its receptor CXCR4. These changes were accompanied by decreased levels of phospho-Akt and gelatinase activity of MMP9, which are downstream effectors of SDF1-CXCR4 signaling. These data point to an important role for DPPIV in suppressing NB development and progression.
Results
DPPIV is expressed in normal neural crest-derived structures and decreased in NB-derived cell lines DPPIV expression was readily observed by reverse transcription (RT-PCR) in rat neural crest-derived structures, including dorsal root ganglia, superior cervical ganglia and sciatic nerve ( Figure 1A ). Immunohistochemical analysis of a normal human tissue microarray revealed DPPIV expression in the adrenal glands and peripheral nerves, and DPPIV expression was comparable to that of thymus tissue that is known to express DPPIV. However, DPPIV expression was not detectable in thyroid gland tissues in the same array, demonstrating the tissue-specific expression of DPPIV. ( Figure 1B ). We then examined the cell surface expression of DPPIV in a panel of NB-derived cell lines, including SK-N-SH, SH-SY5Y, SMS-KCN, SMS-KCNR, SK-N-MC, SK-N-DZ, SK-N-AS and SK-N-F1. As compared with neural crest-derived melanocytes, cell surface expression of DPPIV was greatly decreased or almost undetectable in all cell lines tested except SMS-KCN, which showed moderate levels of DPPIV ( Figure 1C ). The DPPIV enzyme activities in these cell lines correlated with the levels of cell surface protein expression. Melanocyte DPPIV enzyme activities ranged from 180 to 220 pmol/mg protein/min, whereas in SMS-KCN, enzyme activities ranged from 80 to 90 pmol/mg protein/min. In all the other cell lines tested, DPPIV enzyme activities were reduced to 30-50 pmol/mg protein/min ( Figure 1D ). Furthermore, differentiation of SK-N-SH cells with 3 0 ,5 0 -cyclic monophosphate (dbcAMP) ( Figure 1Ea ) resulted in upregulation of DPPIV mRNA levels in association with increased expression of a known differentiated neural marker, microtubule-associated protein 2 (MAP2) ( Figure 1Eb ). Thus, the presence of DPPIV in differentiated neuronal cells and its absence in NB-derived cells suggest that DPPIV loss correlates with NB development and/or progression.
DPPIV induces differentiated phenotype in NB cells (SK-N-SH and SK-N-AS)
To further understand the functional role of DPPIV in NB, we established SK-N-SH and SK-N-AS cell lines stably expressing DPPIV under the control of a tetracycline-responsive promoter. Stable restoration of DPPIV cell surface expression was confirmed by immunofluorescence staining (Figure 2A ). These stable cell lines retained the catalytic activity as demonstrated by peptidase enzyme activity ranging from 160 to 200 pmol/mg protein/min and was comparable to the normal melanocytes (180-220 pmol/mg protein/min) ( Figure 2Ba ). Furthermore, RT-PCR clearly indicated that the levels of DPPIV mRNA in transfected cells were similar to the physiological levels seen in normal human adrenal glands ( Figure 2Bb ). Restoration of DPPIV expression resulted in morphological changes in these cells. Parental and vector-transfected SK-N-SH and SK-N-AS cells grew in a disorganized array of focal clumps. In contrast, SK-N-SH and SK-N-AS cells expressing DPPIV for 10-14 days acquired either neuronal-like or larger flat epithelial-like phenotypes (Figure 2Ca ). Neurite length was significantly increased in SK-N-SH cells re-expressing DPPIV, indicating neuronal differentiation ( Figure 2Cb ). Changes in phenotype of these cells was associated with increased expression of the neural marker MAP2 ( Figure 2D ). Not surprisingly, the proliferation rate was greatly decreased in both cell types as detected by decreased number of viable cells ( Figure 2E ). These data show that DPPIV inhibits NB proliferation in vitro by promoting differentiation.
DPPIV induces apoptosis in NB cells (SK-N-AS) through caspase activation and decreased Akt phosphorylation
Acquiring resistance to apoptosis is a critical step in NB growth and progression. Our data show that DPPIV increases sensitivity of SK-N-AS cells to apoptosis in serum withdrawal conditions. Cells undergoing apoptosis exhibited decreased cell size, round morphology and cellular fragmentation. The proportion of apoptotic cells 3 days following serum withdrawal ranged from 25 to 30% in DPPIV-expressing cells, whereas the control cells exhibited significantly lower percentage (5-7%) of apoptosis ( Figure 3A ). Induction of apoptosis by DPPIV was mediated through activation of both intrinsic and extrinsic apoptotic pathways as shown by generation of cleaved caspase 8 as well as caspase 9, leading to activation of caspase 3, the downstream effector ( Figure 3B ). Furthermore, Akt showed a marked decrease in phosphorylated levels at site Ser-473, in SK-N-AS cells that re-expressed DPPIV compared with control SK-N-AS cells ( Figure 3C ). DPPIV inhibitor diprotin A greatly decreased the DPPIV-induced caspase activation and restored the Akt phosphorylation. These data demonstrate a role for DPPIV in interrupting the survival signaling pathways that may contribute to NB growth and progression.
DPPIV inhibits SDF1-induced NB cell migration, invasion, and angiogenesis in vitro Cell migration and invasion are known to be facilitated by chemokines, including SDF1 and its receptor CXCR4. In a wound-induced migration assay, control SK-N-AS cells treated with SDF1 migrated to fill the wounded area after 24 h of wounding, indicating their strong migratory potential. However, restoration of DPPIV greatly reduced this SDF1-mediated migratory potential as indicated by an unfilled wound area after 24 h ( Figure 4A , bottom panel). Furthermore, the ability of DPPIV-expressing SK-N-AS cells to invade through Matrigel-coated filters was significantly reduced when compared with control SK-N-AS cells. This effect of DPPIV was blocked by diprotin A pretreatment, indicating the specific effects of DPPIV enzyme activity ( Figure 4B ). Angiogenesis is necessary for tumor cell growth and metastasis. Therefore, we determined the effect of DPPIV on the formation of pro-angiogenic structures arising from human umbilical cord vein endothelial cell (HUVEC). Control SK-N-AS cells stimulated the angiogenic process as indicated by the formation of closed intercellular compartments, whereas DPPIV re-expressing SK-N-AS cells showed a greatly decreased ability to form closed intercellular compartments and this effect was blocked by DPPIV inhibitor (Figure 4Ca ). The length of tubular structures in SK-N-AS þ DPPIV cells was significantly shorter than those from control SK-N-AS cells (52% reduction; Po0.05) ( Figure 4Cb ). These effects were accompanied by decreased activities of matrix metalloproteinase MMP9, a pro-angiogenic and invasive factor, as shown by in situ gelatinase activity ( Figure 4Da ) and gel zymography ( Figure 4Db ). Interestingly, diprotin A treatment resulted in restoration of MMP9 activity, indicating the specific effects of DPPIV on decreasing MMP9 levels. Taken together, these results demonstrate that restoration of DPPIV expression attenuates the malignant phenotype of NB cells in vitro.
DPPIV suppresses the tumorigenic potential of NB cells (SK-N-AS) in athymic nude mice We examined the effects of DPPIV on SK-N-AS xenografts in nude mice. Tumors grew in all five mice injected with vector control SK-N-AS cells. However, mice injected with SK-N-AS cells re-expressing DPPIV showed no tumor growth except one animal that developed a tumor at a greatly reduced rate ( Figure 5A ). This tumor was available for immunohistochemistry. TdT-mediated dUTP nick end labeling (TUNEL) assay clearly indicated an increased number of apoptotic cells in the DPPIV-expressing SK-N-AS tumor (Figure 5Ba ). Quantification of TUNEL-positive cells revealed significant increase in apoptosis (25-30%) in DPPIV-expressing SK-N-AS tumors when compared with control tumor (4-6%) (Figure 5Bb ). Furthermore, tumors in control mice were highly angiogenic and showed increased CD31 positivity as compared to the tumor developed from SK-N-AS þ DPPIV cells ( Figure 5C ). These data suggest that DPPIV suppresses NB tumor growth in vivo through induction of apoptosis and probably through inhibition of angiogenesis.
DPPIV downregulates chemokine SDF1 and its receptor CXCR4 in NB (SK-N-AS) cells Chemokines and their receptors play critical roles in tumor growth and metastasis. To examine whether DPPIV's effects on NB cells (SK-N-AS) are mediated through regulation of chemokines and their receptors, we screened a chemokine pathway-specific PCR array. RNAs from control SK-N-AS and DPPIV re-expressing SK-N-AS cells were analysed in parallel. Interestingly, DPPIV re-expression resulted in downregulation of 13 genes, 7 of which were downregulated more than fivefold. In contrast, nine genes that showed upregulation were changed by only 2-to 3-fold ( Figure 6a ). Because SDF1 and CXCR4 showed significant downregulation (24-and 7-fold, respectively), their mRNA and protein levels were further validated by quantitative real-time RT-PCR ( Figure 6b ) and immunofluorescence staining (Figure 6c ). These results suggest that DPPIV negatively regulates NB cell growth through interruption of chemokine signaling.
Discussion
Although dysregulated protease expression has been recognized as a hallmark of cancer, our understanding of proteases that function as tumor and/or metastasis suppressors is limited. Recently, cell surface proteases, including DPPIV and neutral endopeptidase, have emerged as important tumor suppressor genes for prostate, ovarian and lung cancers, as well as hepatocarcinoma and melanoma (Wesley et al., 1999 (Wesley et al., , 2004 (Wesley et al., , 2005 Dai et al., 2001; Terauchi et al., 2005; Kajiyama et al., 2006) . However, the role of cell surface proteases in suppressing NB is virtually unknown. Our studies have shown that DPPIV is expressed in neural crestderived structures, and in agreement with earlier observations in other human neoplasias, DPPIV expres- sion is greatly decreased in NB-derived cells, suggesting that DPPIV is a potential tumor suppressor gene for NB. In support of this idea, we have demonstrated that DPPIV indeed suppresses the malignant phenotype of NB cells, characterized by inhibition of survival, migration/invasion, angiogenesis and tumor growth in nude mice. It is intriguing that a cell surface peptidase can have such pleiotropic effects on the malignant phenotype of NB cells. One possible explanation is that DPPIV degrades or inactivates growth factors and chemokines required for growth and survival of neuroblastic cells. Also, DPPIV may modulate the extracellular microenvironment through its interaction with cell surface receptors and ECM components, thereby providing inhibitory effects on tumor progression.
Children with aggressive and metastatic NB are highly refractory to current treatments and have poor survival rates (Maris and Woods, 2008; Matthay, 2008) . Thus, further understanding the mechanisms that facilitate aggressive tumor growth and identifying the molecules that inhibit this process is of great importance. Recent studies provide compelling evidence that dysregulation of chemokine-receptor signaling, including SDF1-CXCR4, is associated with growth and metastasis of NB and many other types of cancers (Geminder et al., 2001; Payne and Cornelius, 2002 2004; Tran et al., 2004; Belmadani et al., 2005; Burger and Kipps, 2006; Scala et al., 2006; Guyon and Nahon, 2007; Singh et al., 2007; Airoldi et al., 2008) . Although, no CXCL12-driven chemotaxis of NB cells was observed by Airoldi et al. (2006) , other studies have shown that SDF1-CXCR4 expression correlates with aggressive NB with increased migratory potential and higher vascularity in tumors. Furthermore, autocrine stimulation of CXCR4 by its ligand SDF1 was shown to be necessary for the survival of some NB cells in vitro (Geminder et al., 2001; Nevo et al., 2004; Russell et al., 2004; Vasudevan et al., 2005) . Despite these important observations, the mechanisms responsible for activation of the SDF1-CXCR4 pathway remain elusive.
DPPIV is known to regulate the function of certain chemokines. Thus, loss of DPPIV allows accumulation of these chemokines leading to increased interaction with their receptors, and activation of downstream signaling molecules. In support of this view, our studies demonstrate that DPPIV decreases the expression of chemokines in NB cells. It is noted that SDF1 and its receptor CXCR4 were downregulated by more than fivefold. SDF1 and CXCR4 produced by tumors and stromal cells not only promote migration but also can stimulate growth, survival and angiogenesis through activation of survival signaling pathways, and MMP9 required for degradation of nearby matrix (Rundhaug, 2005; Zigrino et al., 2005; Raman et al., 2007) . In fact, DPPIV re-expressing SK-N-AS cells showed decreased MMP9 activity and exhibited reduced in vitro angiogenic and migratory potential. These effects were overcome by pretreatment with diprotin A that resulted in restoration of MMP9. Diprotin A is a competitive inhibitor of DPPIV enzyme activity and thus it appears that DPPIV enzyme activity is required for suppressing the angiogenic and migratory potential of NB cells. In addition, DPPIV also stimulated an apoptotic cascade by activating caspases 8 and 9 as well as their downstream effector caspase 3. These effects of DPPIV were linked to decreased levels of phospho-Akt, the downstream effectors of SDF1-CXCR4 signaling. Interestingly, DPPIV inhibitor diprotin A greatly blocked the DPPIV-induced caspase activation with the increased levels of phosphorylated Akt. Furthermore, evaluation of tumor growth in vivo revealed that inhibited tumor growth of SK-N-AS cells by DPPIV was associated with increased apoptosis and decreased angiogenesis.
These functions of DPPIV may be mediated through regulating SDF1-CXCR4 signaling pathway. DPPIV is shown to inactivate SDF1 by proteolytic cleavage. Interestingly, DPPIV also interacts with CXCR4 in hematopoietic cells. However, such interactions have not yet been identified in neuronal cells. Our studies have shown that DPPIV decreases the levels of both SDF1 and its receptor CXCR4. In fact, it has been reported that SDF1 not only stimulates CXCR4 signaling but also regulates its expression by positive feedback mechanism. It is possible that in neural crestderived cells, DPPIV disrupts this positive autocrine signaling loop not only by direct cleavage of SDF1 but also by associating with receptor CXCR4 eventually leading to decreased levels of CXCR4. Independent of its protease activity, DPPIV has other functions, including binding to ECM and other proteins such as CD45, and adenosine deaminase as shown in hematopoietic cells (Havre et al., 2008) . It will be of great importance to elucidate the specific mechanisms by which DPPIV regulates SDF1-CXCR4 in NB-derived cells. This interruption of the SDF1-CXCR4 axis is probably of significance for inhibition of growth and metastasis of NB (Meitar et al., 1996; Eggert et al., 2000; Geminder et al., 2001; Russell et al., 2004; Tran et al., 2004; Tucker, 2004) .
In summary, our data strongly support a role for DPPIV as a potential tumor suppressor gene for NB. Given its ability to regulate differentiation, apoptosis, angiogenesis and cell motility through its modulation of chemokines and the ECM, DPPIV provides a new and potentially significant approach for the development of treatment strategies aimed at blocking mitogenic and angiogenic signaling. Thus, an emerging appreciation for the role of proteases in suppressing the malignant phenotype could prove especially beneficial in understanding and treating tumors such as NB.
Materials and methods
Tissues and cell culture Superior cervical and sensory dorsal root ganglia, and sciatic nerve were obtained from Sprague-Dawley rats (Charles River Laboratory, Wilmington, MA, USA). Human NB-derived cell lines, SK-N-AS, SK-N-SH, SK-N-DZ, SK-N-MC, SK-N-F1 and SH-SY5Y were from American Type Culture Collection (ATCC, Manassas, VA, USA), and SMS-KCN and SMS-KCNR cells were kindly provided by Children's Oncology Group. The cells were grown in RPMI with 10% fetal bovine serum. Normal human melanocytes were grown in media supplied by the provider (BioWhitaker, Walkersville, MD, USA). To induce differentiation, SK-N-SH cells were treated with 1 mM dibutyryl cyclic Amp (dbcAMP) (Sigma Aldrich, St Louis, MO, USA) for 8 days.
Immunohistochemical analysis
Human tissue microarrays were obtained from Cybrdi (Frederick, MD, USA). After deparaffinization, slides were incubated with target retrieval solution (Dako, Carpentaria, CA, USA). Staining was performed using the rabbit Immuno-Cruz staining system (Santa Cruz Biotechnology, Santa Cruz, CA, USA) according to the manufacturer's protocol. Anti-DPPIV antibody (Biomol, Plymouth Meeting, PA, USA) was used at 1:400. Normal rabbit IgG was used as a negative control. Goat anti-rabbit Cy3-conjugated secondary antibody (Jackson Laboratories, Bar Harbor, ME, USA) was used at 1:500. DAPI was used as a nuclear stain (Molecular Probes, Eugene, OR, USA). Tumor specimens were processed for staining as described above. Anti-CD31 (Fisher Scientific, Fremont, CA, USA) was used at 1:200. Apoptosis was detected by TUNEL assay using an APOPTAG kit (Chemicon International Inc., Temecula, CA, USA) according to the manufacturer's protocol. Slides were viewed using a Nikon ECLIPSE TE2000-U inverted microscope connected to a RT Slider Spot digital camera (Diagnostic Instruments, Sterling Heights, MI, USA). Images were acquired using the SPOT software version 3.2.
Semiquantitative RT-PCR cDNAs synthesized from total RNA (2 mg) using superscript-II reverse transcriptase (Invitrogen, Carlsbad, CA, USA) were used as templates for RT-PCR. Primer sets used: DPPIV (5 0 -tcatatgacatttatgattta-3 0 and 5 0 -caaaatgaggaggcaagatcatc-3 0 ), MAP2 (5 0 -tgtcacagtggaggaagcag-3 0 and 5 0 -cctgggatagctag gggttc-3 0 ) and GAPDH as a control (5 0 -atcttccaggagcgagatcc-3 0 and 5 0 -accactgacacgttggcagt-3 0 ). PCR amplification was carried out as described earlier (Wesley et al., 2005) .
Flow cytometry
Cell surface expression of DPPIV was determined using an EPICS XL/XL-MCL Flow Cytometry System (Beckman Coulter, Fullerton, CA, USA). Cells were stained with DPPIV primary antibody (S27 mAb; ATCC). Fluorescein-conjugated rabbit anti-mouse IgG (Dako) was used as the secondary antibody. Cells stained with only IgG were analysed in parallel as negative controls.
DPPIV enzymatic activity DPPIV peptidase activity was measured by colorimetric assay using Gly-Pro p-nitroanilide substrate, as described earlier (Wesley et al., 2005) .
Establishment of in vitro model system SK-N-AS and SK-N-SH cells were co-transfected with the tetracycline-inducible pTRE vector containing DPPIV cDNA and the selectable plasmid pTET-on (Clontech, Mountain View, CA, USA), using lipofectamine reagent (Invitrogen). Stably transfected cells were selected in the presence of G418 (400 mg/ml) and screened for DPPIV expression. Cells transfected with the vector alone were used as controls.
Immunofluorescence microscopy
Cells grown on coverslips were stained with the respective mAbs (S27, SDF1, CXCR4 and MAP2; Santa Cruz Biotechnology) and incubated with either AlexaFluor 488 (Invitrogen) or Cy3-conjugated secondary antibodies at 1:500 dilution. Cells were counterstained with DAPI. Stained cells were viewed and imaged with an inverted microscope.
Measurements of neurite-like outgrowth
Cells possessing neurite-like processes longer than the diameter of the cell body were considered to be positive for counting. Images of the cells were captured with an inverted microscope. All neurites in each region of interest were manually traced and the length was measured using the SPOT software. The average neurite length was calculated by dividing the sum of neurite length by the number of cells in each region of interest. For each group, at least 100 cells in 10 randomly selected fields were measured. The data are presented as mean values ± s.d.
MTT cell proliferation assay
Control and DPPIV-transfected cells were plated in triplicate on 96-well plates and cultured in the presence of doxycycline (1 mg/ml). Colorimetric 3-(4,5-dimethylthiazolyl-2)-2, 5-diphenyl tetrazolium bromide (MTT) assays were performed on day 3 following the manufacturer's instructions (ATCC). The absorbance of released purple formazan was measured at 570 nm. The experiment was repeated twice and the data are presented as mean values ± s.d.
Detection of apoptotic cells by TUNEL assay
Parental, vector control and DPPIV-transfected SK-N-AS cells were cultured in media with or without serum for 48 h in the presence of doxycycline (1 mg/ml). DPPIV-transfected SK-N-AS cells were cultured in the presence or absence of 5 mM diprotin A (Sigma Aldrich). Cells were fixed in 1% paraformaldehyde and ice-cold 70% ethanol. TUNEL assay was performed following the manufacturer's instructions and the percentage of apoptosis was determined using flow cytometry.
Wound-induced cell migration assay and Matrigel cell invasion assay Cell monolayers were wounded with a sterile micropipette tip and fed with a medium containing SDF1 (100 ng/ml). Cells were photographed at 2 and 24 h after wounding using a phase-contrast microscope. Invasion was assessed using Matrigel-coated Biocoat cell culture inserts (BD Biosciences, Bedford, MA, USA) with 8 mm pores in 24-well plates. A total of 3 Â 10 4 cells were placed in the upper compartment and the lower compartment was filled with 500 ml growth medium containing SDF1 (100 ng/ml). DPPIV-transfected SK-N-AS cells were cultured in the presence or absence of 5 mM diprotin A for 15 min at 37 1C. After 24 h, cells on the lower surface were stained with crystal violet and solubilized in extraction buffer. Optical density values at 540 nm correlating with cell migration were plotted. Results are presented as mean values ± s.d. of triplicate.
In vitro angiogenesis assay Matrigel matrix (15 ml) (BD Biosciences) was distributed per well in a 96-well plate. HUVECs (ATCC) (7 Â 10 3 cells per well) suspended in 100 ml of RPMI supplemented with 0.2% FBS were added to each well and co-cultured in triplicate with 7 Â 10 3 of either SK-NAS, SK-NAS þ vector or SK-NAS þ DPPIV cells at 37 1C. DPPIV activity was inhibited by pretreatment of cells with 5 mM diprotin A for 15 min at 37 1C. After 20 h, images were captured and the total length of tubelike angiogenic structures of five randomly chosen microscopic fields was measured by the Image J software (NIH, Bethesda, MD, USA).
MMP9 gelatinase activity
For gelatin zymography, 10 mg protein from each cell supernatant was applied to 10% SDS-polyacrylamide gel electrophoresis gels containing gelatin-A (1 mg/ml; Sigma Aldrich). After electrophoresis, gels were washed in 2.5% Triton X-100, incubated for 18 h at 37 1C and stained in 0.1% Coomassie brilliant blue. The gelatinolytic regions were observed as white bands against a blue background. In situ detection of gelatinolytic activity was carried out by overlaying cells grown in an eight-well chamber slide with 100 mg/ml quenched fluorescein-labeled gelatinase substrate, DQ-gelatin (Molecular Probes) for 2 h at 37 1C. Slides were fixed with 4% paraformaldehyde, and imaged using an inverted microscope.
Western blot analysis
Total protein (30 mg) was separated by SDS-polyacrylamide gel electrophoresis and probed with respective antibodies (1:1000 for phospho-Akt (Ser-473), total Akt and caspases 3, 8 and 9; Cell Signaling, Danvers, MA, USA; 1:500 for actin; Sigma Aldrich), followed by incubation with secondary antibody conjugated to horseradish peroxidase at room temperature for 1 h. Signals were developed with chemiluminescence using a PerkinElmer ECL kit (Waltham, MA, USA). Total Akt and actin were used as loading controls.
Tumorigenicity in nude mice BALB/c (nu/nu) nude mice (6 week old; Taconic, Hudson, NY, USA) were injected subcutaneously into the flanks with 5 Â 10 6 control and DPPIV re-expressing SK-N-AS cell suspension in Matrigel (BD Biosciences). Five animals were used in each group. All mice were fed doxycycline-containing food (Bio-Serve, Frenchtown, NJ, USA). Tumor volume was estimated by using the formula width 2 Â length Â 0.52 in cm 3 . At day 29, mice were euthanized, and the tumors were removed for further experiments. Animal experiments were approved by the Institutional Animal Care and Use Committee. Apoptosis and tumor vascularity were assessed in each tumor specimen as described above. For quantification of apoptosis, the number of TUNEL-positive cells was counted in a total of six high-power fields and expressed as mean percentage of total cells in these fields of the tumor.
Chemokine pathway-focused gene expression profiling by real-time quantitative RT-PCR A PCR array (PAHS-022A; SuperArray, Frederick, MD, USA) that profiles the expression of 84 genes encoding chemokines and their receptors was used according to the manufacturer's protocol. Briefly, the cDNA generated from 2 mg of total RNA was combined with SYBR green qPCR master mix. Equal aliquots of this mixture were added to each well of the PCR array plates containing pre-dispensed gene-specific primer sets. Quantitative RT-PCR analysis was performed in an Applied Biosystems Prism 5700 Sequence Detection system and analysed using the GeneAmp 5700 SDS software. Relative quantification was performed using standard curves generated for each gene-specific primer pair. The values obtained from each set of gene-specific primers were normalized to endogenous control genes and used to determine relative expression levels. Levels of SDF1 and CXCR4 mRNA were further validated using assay on demand primer sets (Applied Biosystems, Foster City, CA, USA).
Statistical analysis
All in vitro studies were performed in triplicate and results are expressed as mean ± s.d. Statistical significances were determined by means of Student's t-test or by analysis of variance and multiple comparisons test. A probability Po0.05 was considered statistically significant in all calculations.
